Immediately upon closing the transaction, the company will take over the Cialis business.
How Are Regulatory and Patent Policies Affecting Tadalafil?
In the U.S., recent growth has come from higher realized prices as the pharma anticipates the looming patent cliff. "We expect that the entry of generic competition following the loss of exclusivity will cause a rapid and severe decline in revenue," the company stated in its year-end filing with the Securities and Exchange Commission. Such a steep decline will be a heavy blow for Lilly's bottom line, even if it comes a year later than previously expected. Lilly has weathered major patent losses before. In 2013, sales of its antidepressent and pain drug Cymbalta everyday cialis cost (duloxetine) topped $5 billion — only to collapse down to $1.6 billion the next year after its patent protection expired.
Competitive Landscape
This time, though, Lilly hopes a group of newly approved and launched drugs — headlined by Trulicity (dulaglutide) and Taltz (ixekizumab) — can keep revenue growth on track. "With regards to learnings from our YZ experience, the biggest difference is the fact that with this next wave of patent expiries we are able to offset that with new product launches," said Derica Rice, Lilly's CFO, on a recent earnings call, referring to a period of time between 2011 and 2014. That narrative took a hit, though, when Lilly failed to win U.S. approval for baricitinib, a closely watched drug for rheumatoid arthritis. Lotus Pharmaceuticals has acquired trademark, marketing authorization, and manufacturing know-how of Tadalafil 2.5mg, 5mg, 10mg and 20mg under the brand name of Cialis in Taiwan for $57.5 million from Eli Lilly and Company. The completion of this transaction is subject to customary closing conditions. Tadalafil is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty. According to IQVIA data, the total sales of Cialis in Taiwan for the last 12 months as of December 31, 2021 were approximately $15.7 million. The Company believes the majority of Cialis sales are driven by drugstore channel. Cialis is the 2nd largest brand by revenue in Taiwan indicated for erectile dysfunction with very high brand loyalty.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Black | 80mg | 30 + 2 Pills | 89.11€ 84.87€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Cialis Professional | 20mg | 120 + 4 Pills | 291.68€ 277.79€ | |
| Cialis Professional | 20mg | 60 + 2 Pills | 183.83€ 175.08€ | |
| Cialis Super Active | 20mg | 30 + 6 Pills | 128.09€ 121.99€ | |
| Cialis Generic | 2.5mg | 10 Pills | 28.51€ 27.15€ | |
| Cialis Generic | 60mg | 180 + 10 Pills | 313.11€ 298.20€ | |
| Cialis Professional | 20mg | 270 + 6 Pills | 623.07€ 593.40€ | |
| Cialis Professional | 20mg | 180 + 4 Pills | 423.11€ 402.96€ | |
| Cialis Generic | 2.5mg | 30 + 4 Pills | 51.95€ 49.48€ |
The acquisition will accelerate Lotus's growth and sets a very strong foundation for entry in the high growth drugstore channel.
Cialis vs. Tadalafil: Frequently Asked Questions
Under the settlement agreement, Cialis exclusivity will end at the earliest on September 27, 2018. That date is nearly a year after Lilly expects to lose patent protection on other compound and use patents which cover the drug through November 2017. In a statement, Lilly's general counsel Michael Harrington said the agreement provides Lilly with more certainty around its U.S. exclusivity. With the agreement, Lilly extends the runway for Cialis, staving off a more immediate blow to revenues.
Brand Choices
That generic threat still looms in the near-future, however, and will post a challenge to Lilly's financial growth. The Indianapolis drugmaker has committed to hitting 5% annual revenue growth through 2020, betting a wave of new drugs will help see it through another rough patch of patent expiries. Copycat versions of Eli Lilly's ADHD drug Strattera (atomoxetine) launched earlier this year, and the company anticipates losing exclusivity for its blood-thinner Effient (prasugrel) in October. A recent legal victory in the U.K.'s top court, however, should help Lilly defend its cancer drug Alimta (pemetrexed), which also faces inbound rivals. Cialis is Lilly's second best-selling product and accounted for nearly 12% of total revenues last year with $2.47 billion in sales. Thermo Fisher Scientific opens flag.. 29 April 2026 Amcor invests $35 M in advanced hea.. 26 April 2026 Singapore and buy cialis uk cheap Japan deepen collabor.. 23 April 2026 Japan's Takeda terminates mRNA-targ.. 18 April 2026 Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (Tadalafil) and Alimta (Pemetrexed), from Eli Lilly and Company for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis, a leading men's health product for the treatment of erectile dysfunction. "This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world's leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia," said John Graham, Group CEO, Zuellig Pharma.
- Ongoing research may explore new formulations or delivery methods.
- Studies on its potential effects in other conditions (e.g., Raynaud's) exist.
- Investigation into cardiovascular benefits remains a topic of interest.
- The role of daily tadalafil in early-stage Peyronie's disease is studied.
- Post-generic, Lilly's focus shifted to newer therapeutic areas.
- Real-world data collection continues to inform long-term use patterns.
- Patient adherence and persistence with therapy are research subjects.
- The legacy of Cialis as a blockbuster drug influences pharmaceutical R&D.
INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis was approved for erectile dysfunction (ED) in the EU in 2002.
About the Company
IMS numbers vary from those of ImpactRx primarily because IMS data represent aggregated pharmacy sales, reflecting what is filled at the pharmacy including new prescriptions for continuing users and prescriptions called in by phone. "The Three PDE 5 Inhibitors Sildenafil, Tadalafil And Vardenafil - Results Of A Comparative Preference Trial In 222 Patients With Erectile Dysfunction," Hartmut Porst, et. al., presented in poster session at American Urological Association Annual Meeting, May 2004. Computed from IMS NPA PlusTM, April 2004. The Likely Worldwide Increase in Erectile Dysfunction Between 1995 and 2025 and Some Possible Policy Consequences.
Regulatory Approvals
Back To Great Sex: Overcome ED and Reclaim Lost Intimacy. Singapore, 5 February 2024 Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction. ZP Therapeutics, the commercial division of Zuellig Pharma, will promote the two brands in the relevant markets. Prior to the acquisition, ZP Therapeutics was responsible for the promotion and distribution of the brands as part of a broader, long-term strategic partnership with Lilly in Brunei, Indonesia, Malaysia, Philippines and Thailand. Cialis for once daily use was approved to treat ED in the EU in 2007. "With this approval, Cialis is now the only medication in the EU to provide a single treatment option for men with both ED and BPH," said Anthony Beardsworth, senior medical director at Lilly. "Since many men who have ED also experience the signs and symptoms of BPH, a single medication approved to treat both may be a useful therapeutic option for men and physicians." Cialis 5 mg for once daily use was approved by the U.S.
What Are the Financial Trajectories and Revenue Projections?
“This acquisition marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. We look forward to further expanding our commercial presence in the region through meaningful strategic partnerships with the world’s leading biopharma companies as we remain focused on our purpose of making healthcare more accessible to communities in Asia,” said John Graham, Group CEO, Zuellig Pharma. Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees.
How long does it take for Cialis to work?
Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world. ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 cialis canada without prescription countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community. Eli Lilly doesn't expect to see generic competition to its second best-selling drug Cialis (tadalafil) until after September 2018, announcing Wednesday it had entered into a settlement agreement with generic drugmakers to resolve pending patent litigation over the erectile dysfunction treatment. Lilly had been battling generic companies in federal district court over a patent covering Cialis' unit dose, which was previously due to expire in April 2020. Food and Drug Administration (FDA) in October 2011 for the treatment of the signs and symptoms of BPH. The FDA also approved Cialis 5 mg for once daily use to treat men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH).
| Procedure | Details | Notes |
|---|---|---|
| Dispensing Standards | Store in original packaging, protected from light | Ensures stability |
| Inventory Management | Rotate stock to avoid expiration | FIFO method |
| Prescribing Regulations | Must be prescribed by authorized healthcare provider | Legal compliance |
| Disposal of Expired Drugs | Follow hazardous waste disposal protocols | Prevent environmental contamination |
In addition to the U.S.
- Cialis Lilly differentiates itself with a well-established safety record over more than a decade.
- The company provides healthcare professionals with comprehensive prescribing information.
- Lilly emphasizes personalized care, tailoring dosage to patient response.
- Online telehealth services now often provide prescriptions for Cialis Lilly with proper evaluation.
- Cialis Lilly should be used cautiously with other ED therapies or herbal supplements.
- It does not cause dependency but requires proper medical oversight.
- Patient support programs include counseling and adherence guidance.
- Cialis Lilly’s impact is enhanced by addressing psychological factors affecting ED.
- It plays a role in managing the sexual health of men with chronic conditions.
- Regulatory authorities monitor adverse event reports to ensure ongoing safety.
and EU, Cialis for once daily use has been approved to treat the signs and symptoms of BPH in Canada, Mexico, Brazil, South Korea, Russia, Panama, Argentina, Honduras, Ecuador, Costa Rica, Colombia and Israel. It is important to note that Cialis is not to be taken with medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate, which are often prescribed for chest pain, or with recreational drugs called "poppers" like amyl or butyl nitrite, as the combination may cause an unsafe drop in blood pressure.
| Parameter | Details | Notes |
|---|---|---|
| Absorption | Rapid, within 30-60 minutes | Food may delay absorption |
| Duration of Action | Up to 36 hours | Variable depending on individual |
| Metabolism | Primarily via CYP3A4 enzyme | Liver metabolism |
| Elimination Half-life | Approximately 17.5 hours | Long half-life allows flexible dosing |